Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · April 26, 2023

Pembrolizumab and Cabozantinib in Patients With Recurrent Metastatic HNSCC

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial
Nat. Med. 2023 Apr 03;[EPub Ahead of Print], NF Saba, CE Steuer, A Ekpenyong, A McCook-Veal, K Magliocca, M Patel, NC Schmitt, W Stokes, JE Bates, S Rudra, J Remick, M McDonald, M Abousaud, AC Tan, MZH Fadlullah, R Chaudhary, J Muzaffar, K Kirtane, Y Liu, GZ Chen, DM Shin, Y Teng, CH Chung

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading